EUVIMEDEUVIMED entdecken
Crossref

Assessing the impact of aprepitant on response to dose-intensive cyclophosphamide, etoposide, and cisplatin (DICEP)

Kevin Thai iD, Jennifer Jupp, Deonne Dersch-Mills, Sunita Ghosh, Mona Shafey, Leanne Fong

Journal of Oncology Pharmacy Practice · 2025

DOI: 10.1177/10781552241269722 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Oncology Pharmacy Practice, 2025. Verfasst von Kevin Thai und 5 weiteren Autor:innen. Beteiligte Einrichtung: Tom Baker Cancer Centre, Calgary, Alberta, Canada. Hauptthemen laut MEDLINE: Aprepitant, Antineoplastic Combined Chemotherapy Protocols, Antiemetics, Hodgkin Disease. Die Arbeit nennt 22 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Despite evidence demonstrating the effectiveness of aprepitant for chemotherapy-induced nausea and vomiting (CINV), its use in stem cell transplant settings across Canada is not standard. While pharmacokinetic data exists, the clinical significance of cytochrome P450 3A4 (CYP 3A4) inhibition of cyclophosphamide by aprepitant is unclear. Reduced activation of cyclophosphamide may reduce the effectiveness of dose-intensive cyclophosphamide, etoposide, and cisplatin (DICEP).

Objectives

To compare response rates to DICEP in patients with Hodgkin lymphoma (HL) and diffuse large B-cell lymphoma (DLBCL) in the presence and absence of aprepitant.

Methods

A retrospective review of patients who received full-dose DICEP for relapsed/refractory HL or DLBCL between June 1995 and September 2018 at the Foothills Medical Centre (FMC) in Calgary, Alberta, Canada was conducted. Descriptive statistics were used to assess response rate, as defined by the 2007 International Working Group response criteria.

Results

Of the 218 patients included in this study, 87.6% of patients in the control group and 88.5% of patients in the aprepitant group responded to DICEP (difference 0.025 [95% CI, −0.066 to 0.114], p = 0.827). Univariate analyses for age, sex, type of cancer, stage of cancer, number of prior relapses, and relapse status were not significant. No significant differences were observed for secondary outcomes.

Conclusion

Response rates to DICEP in relapsed/refractory HL and DLBCL patients were similar regardless of aprepitant use. Considering these results and the effectiveness of aprepitant in CINV, its addition to standard antiemetic therapy in patients receiving DICEP should be given strong consideration in the transplant setting.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AprepitantAntineoplastic Combined Chemotherapy ProtocolsAntiemeticsHodgkin DiseaseLymphoma, Large B-Cell, DiffuseHumansEtoposideCisplatinMaleCyclophosphamideRetrospective StudiesFemaleMiddle AgedAdultNauseaVomitingAgedDose-Response Relationship, DrugYoung AdultTreatment Outcome

Stichwörter der Autor:innen

AprepitantCYP 3A4cyclophosphamidedrug interactionlymphoma

Substanzen

AprepitantEtoposideCisplatinCyclophosphamideAntiemetics

Autor:innen und Institutionen

  • Tom Baker Cancer Centre, Calgary, Alberta, Canada.
  • Alberta Health Services, Calgary, Alberta, Canada.
  • Foothills Medical Centre, Calgary, Alberta, Canada.

ORCID-Profile: Kevin Thai

Zitieren

APA

Thai, K., Jupp, J., Dersch-Mills, D., Ghosh, S., Shafey, M., & Fong, L. (2025). Assessing the impact of aprepitant on response to dose-intensive cyclophosphamide, etoposide, and cisplatin (DICEP). Journal of Oncology Pharmacy Practice. https://doi.org/10.1177/10781552241269722

Vancouver

Thai K, Jupp J, Dersch-Mills D, Ghosh S, Shafey M, Fong L. Assessing the impact of aprepitant on response to dose-intensive cyclophosphamide, etoposide, and cisplatin (DICEP). Journal of Oncology Pharmacy Practice. 2025. doi:10.1177/10781552241269722

BibTeX
@article{Thai2025,
  author = {Thai, Kevin and Jupp, Jennifer and Dersch-Mills, Deonne and Ghosh, Sunita and Shafey, Mona and Fong, Leanne},
  title = {Assessing the impact of aprepitant on response to dose-intensive cyclophosphamide, etoposide, and cisplatin (DICEP)},
  journal = {Journal of Oncology Pharmacy Practice},
  year = {2025},
  doi = {10.1177/10781552241269722}
}
Kostenlos starten →